A citation-based method for searching scientific literature

Richard S Finn, John P Crown, Istvan Lang, Katalin Boer, Igor M Bondarenko, Sergey O Kulyk, Johannes Ettl, Ravindranath Patel, Tamas Pinter, Marcus Schmidt, Yaroslav Shparyk, Anu R Thummala, Nataliya L Voytko, Camilla Fowst, Xin Huang, Sindy T Kim, Sophia Randolph, Dennis J Slamon. Lancet Oncol 2015
Times Cited: 1205

List of co-cited articles
682 articles co-cited >1

Times Cited
  Times     Co-cited

Palbociclib and Letrozole in Advanced Breast Cancer.
Richard S Finn, Miguel Martin, Hope S Rugo, Stephen Jones, Seock-Ah Im, Karen Gelmon, Nadia Harbeck, Oleg N Lipatov, Janice M Walshe, Stacy Moulder,[...]. N Engl J Med 2016

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Gabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, Yoon-Sim Yap, Gabe S Sonke, Shani Paluch-Shimon, Mario Campone, Kimberly L Blackwell, Fabrice André, Eric P Winer,[...]. N Engl J Med 2016

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
George W Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A Kaufman,[...]. J Clin Oncol 2017

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Nicholas C Turner, Jungsil Ro, Fabrice André, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Sibylle Loibl, Cynthia Huang Bartlett, Ke Zhang,[...]. N Engl J Med 2015

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Matthew P Goetz, Masakazu Toi, Mario Campone, Joohyuk Sohn, Shani Paluch-Shimon, Jens Huober, In Hae Park, Olivier Trédan, Shin-Cheh Chen, Luis Manso,[...]. J Clin Oncol 2017

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
Nicholas C Turner, Dennis J Slamon, Jungsil Ro, Igor Bondarenko, Seock-Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma,[...]. N Engl J Med 2018

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
Seock-Ah Im, Yen-Shen Lu, Aditya Bardia, Nadia Harbeck, Marco Colleoni, Fabio Franke, Louis Chow, Joohyuk Sohn, Keun-Seok Lee, Saul Campos-Gomez,[...]. N Engl J Med 2019

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
Richard S Finn, Judy Dering, Dylan Conklin, Ondrej Kalous, David J Cohen, Amrita J Desai, Charles Ginther, Mohammad Atefi, Isan Chen, Camilla Fowst,[...]. Breast Cancer Res 2009

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
Dennis J Slamon, Patrick Neven, Stephen Chia, Peter A Fasching, Michelino De Laurentiis, Seock-Ah Im, Katarina Petrakova, Giulia Val Bianchi, Francisco J Esteva, Miguel Martín,[...]. J Clin Oncol 2018

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Debu Tripathy, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Nadia Harbeck, Sara A Hurvitz, Louis Chow, Joohyuk Sohn, Keun Seok Lee,[...]. Lancet Oncol 2018

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
George W Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A Kaufman,[...]. JAMA Oncol 2020

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
Dennis J Slamon, Patrick Neven, Stephen Chia, Peter A Fasching, Michelino De Laurentiis, Seock-Ah Im, Katarina Petrakova, Giulia V Bianchi, Francisco J Esteva, Miguel Martín,[...]. N Engl J Med 2020

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
Stephen R D Johnston, Nadia Harbeck, Roberto Hegg, Masakazu Toi, Miguel Martin, Zhi Min Shao, Qing Yuan Zhang, Jorge Luis Martinez Rodriguez, Mario Campone, Erika Hamilton,[...]. J Clin Oncol 2020

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.
Maura N Dickler, Sara M Tolaney, Hope S Rugo, Javier Cortés, Véronique Diéras, Debra Patt, Hans Wildiers, Clifford A Hudis, Joyce O'Shaughnessy, Esther Zamora,[...]. Clin Cancer Res 2017

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
G N Hortobagyi, S M Stemmer, H A Burris, Y S Yap, G S Sonke, S Paluch-Shimon, M Campone, K Petrakova, K L Blackwell, E P Winer,[...]. Ann Oncol 2018

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
Maria Teresa Herrera-Abreu, Marta Palafox, Uzma Asghar, Martín A Rivas, Rosalind J Cutts, Isaac Garcia-Murillas, Alex Pearson, Marta Guzman, Olga Rodriguez, Judit Grueso,[...]. Cancer Res 2016

The history and future of targeting cyclin-dependent kinases in cancer therapy.
Uzma Asghar, Agnieszka K Witkiewicz, Nicholas C Turner, Erik S Knudsen. Nat Rev Drug Discov 2015

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
José Baselga, Mario Campone, Martine Piccart, Howard A Burris, Hope S Rugo, Tarek Sahmoud, Shinzaburo Noguchi, Michael Gnant, Kathleen I Pritchard, Fabienne Lebrun,[...]. N Engl J Med 2012

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
H S Rugo, R S Finn, V Diéras, J Ettl, O Lipatov, A A Joy, N Harbeck, A Castrellon, S Iyer, D R Lu,[...]. Breast Cancer Res Treat 2019

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021

Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
Fabrice André, Eva Ciruelos, Gabor Rubovszky, Mario Campone, Sibylle Loibl, Hope S Rugo, Hiroji Iwata, Pierfranco Conte, Ingrid A Mayer, Bella Kaufman,[...]. N Engl J Med 2019

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
Nicholas C Turner, Yuan Liu, Zhou Zhu, Sherene Loi, Marco Colleoni, Sibylle Loibl, Angela DeMichele, Nadia Harbeck, Fabrice André, Mohamed Amine Bayar,[...]. J Clin Oncol 2019

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Erica L Mayer, Amylou C Dueck, Miguel Martin, Gabor Rubovszky, Harold J Burstein, Meritxell Bellet-Ezquerra, Kathy D Miller, Nicholas Zdenkowski, Eric P Winer, Georg Pfeiler,[...]. Lancet Oncol 2021

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
Lawrence M Gelbert, Shufen Cai, Xi Lin, Concepcion Sanchez-Martinez, Miriam Del Prado, Maria Jose Lallena, Raquel Torres, Rose T Ajamie, Graham N Wishart, Robert Steven Flack,[...]. Invest New Drugs 2014

Cell cycle, CDKs and cancer: a changing paradigm.
Marcos Malumbres, Mariano Barbacid. Nat Rev Cancer 2009

CDK4/6 inhibition triggers anti-tumour immunity.
Shom Goel, Molly J DeCristo, April C Watt, Haley BrinJones, Jaclyn Sceneay, Ben B Li, Naveed Khan, Jessalyn M Ubellacker, Shaozhen Xie, Otto Metzger-Filho,[...]. Nature 2017

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
Zhiqiang Li, Pedram Razavi, Qing Li, Weiyi Toy, Bo Liu, Christina Ping, Wilson Hsieh, Francisco Sanchez-Vega, David N Brown, Arnaud F Da Cruz Paula,[...]. Cancer Cell 2018

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.
Stephen Johnston, Miguel Martin, Angelo Di Leo, Seock-Ah Im, Ahmad Awada, Tammy Forrester, Martin Frenzel, Molly C Hardebeck, Joanne Cox, Susana Barriga,[...]. NPJ Breast Cancer 2019

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.
David W Fry, Patricia J Harvey, Paul R Keller, William L Elliott, Maryanne Meade, Erin Trachet, Mudher Albassam, XianXian Zheng, Wilbur R Leopold, Nancy K Pryer,[...]. Mol Cancer Ther 2004

The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.
Ben O'Leary, Rosalind J Cutts, Yuan Liu, Sarah Hrebien, Xin Huang, Kerry Fenwick, Fabrice André, Sibylle Loibl, Sherene Loi, Isaac Garcia-Murillas,[...]. Cancer Discov 2018

Cell cycle proteins as promising targets in cancer therapy.
Tobias Otto, Piotr Sicinski. Nat Rev Cancer 2017

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.
Shom Goel, Qi Wang, April C Watt, Sara M Tolaney, Deborah A Dillon, Wei Li, Susanne Ramm, Adam C Palmer, Haluk Yuzugullu, Vinay Varadan,[...]. Cancer Cell 2016

Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
Sunil Verma, Cynthia Huang Bartlett, Patrick Schnell, Angela M DeMichele, Sherene Loi, Jungsil Ro, Marco Colleoni, Hiroji Iwata, Nadia Harbeck, Massimo Cristofanilli,[...]. Oncologist 2016

The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Seth A Wander, Ofir Cohen, Xueqian Gong, Gabriela N Johnson, Jorge E Buendia-Buendia, Maxwell R Lloyd, Dewey Kim, Flora Luo, Pingping Mao, Karla Helvie,[...]. Cancer Discov 2020

Treating cancer with selective CDK4/6 inhibitors.
Ben O'Leary, Richard S Finn, Nicholas C Turner. Nat Rev Clin Oncol 2016

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.
Cynthia X Ma, Feng Gao, Jingqin Luo, Donald W Northfelt, Matthew Goetz, Andres Forero, Jeremy Hoog, Michael Naughton, Foluso Ademuyiwa, Rama Suresh,[...]. Clin Cancer Res 2017

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, M S Aapro, F André, C H Barrios, J Bergh, G S Bhattacharyya, L Biganzoli,[...]. Ann Oncol 2020

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.
Angela DeMichele, Massimo Cristofanilli, Adam Brufsky, Xianchen Liu, Jack Mardekian, Lynn McRoy, Rachel M Layman, Birol Emir, Mylin A Torres, Hope S Rugo,[...]. Breast Cancer Res 2021

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer.
Sara A Hurvitz, Miguel Martin, Michael F Press, David Chan, María Fernandez-Abad, Edgar Petru, Regan Rostorfer, Valentina Guarneri, Chiun-Sheng Huang, Susana Barriga,[...]. Clin Cancer Res 2020

Targeting CDK4 and CDK6: From Discovery to Therapy.
Charles J Sherr, David Beach, Geoffrey I Shapiro. Cancer Discov 2016

Trastuzumab emtansine for HER2-positive advanced breast cancer.
Sunil Verma, David Miles, Luca Gianni, Ian E Krop, Manfred Welslau, José Baselga, Mark Pegram, Do-Youn Oh, Véronique Diéras, Ellie Guardino,[...]. N Engl J Med 2012

Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.
R Condorelli, L Spring, J O'Shaughnessy, L Lacroix, C Bailleux, V Scott, J Dubois, R J Nagy, R B Lanman, A J Iafrate,[...]. Ann Oncol 2018

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.
C Yang, Z Li, T Bhatt, M Dickler, D Giri, M Scaltriti, J Baselga, N Rosen, S Chandarlapaty. Oncogene 2017

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Luigi Formisano, Yao Lu, Alberto Servetto, Ariella B Hanker, Valerie M Jansen, Joshua A Bauer, Dhivya R Sudhan, Angel L Guerrero-Zotano, Sarah Croessmann, Yan Guo,[...]. Nat Commun 2019

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Sandra M Swain, José Baselga, Sung-Bae Kim, Jungsil Ro, Vladimir Semiglazov, Mario Campone, Eva Ciruelos, Jean-Marc Ferrero, Andreas Schneeweiss, Sarah Heeson,[...]. N Engl J Med 2015

Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.